<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597986</url>
  </required_header>
  <id_info>
    <org_study_id>9766-CL-0031</org_study_id>
    <nct_id>NCT01597986</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone</brief_title>
  <official_title>A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basilea Pharmaceutica International Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of multiple doses of isavuconazole on the
      pharmacokinetics (PK) of a single dose of contraceptive in healthy post-menopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) variables for ethinyl estradiol and norethindrone (in plasma): AUCinf , AUClast, and Cmax</measure>
    <time_frame>For Days 1 and 13: predose and 12 times post dose; for Days 2, 3, 4, 5, 14, 15, 16, and 17: one time each day</time_frame>
    <description>AUC from time 0 extrapolated to infinity (AUCinf), Area under the curve (AUC) from time of dosing to last quantifiable concentration (AUClast ), and maximum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK variable for ethinyl estradiol and norethindrone (in plasma): tmax , t1/2 , Vz /F, and CL/F</measure>
    <time_frame>For Days 1 and 13: pre-dose and 12 times post dose; for Days 2, 3, 4, 5, 14, 15, 16, and 17: one time each day</time_frame>
    <description>Time to attain Cmax (tmax) , apparent terminal elimination half-life (t1/2 ), apparent volume of distribution (Vz /F), apparent body clearance after oral dosing (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK variable for isavuconazole (in plasma): Ctrough</measure>
    <time_frame>For Day 11: predose; for Days 12 and 13: predose and 12 times post dose; for Day 14 and 15: predose; and for Day 16: predose and 24 hours post dose</time_frame>
    <description>trough concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK variable for isavuconazole (in plasma): AUCtau, Cmax, and tmax</measure>
    <time_frame>For Days 12 and 13: predose and 12 times post dose</time_frame>
    <description>Area under the concentration-time curve during the time interval between consecutive dosing (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs)</measure>
    <time_frame>Day 1 through Day 24 Â± 2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics of Isavuconazole</condition>
  <condition>Pharmacokinetics of Ethinyl Estradiol and Norethindrone</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Isavuconazole and oral contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isavuconazole</intervention_name>
    <description>oral</description>
    <arm_group_label>Isavuconazole and oral contraceptive</arm_group_label>
    <other_name>BAL8557</other_name>
    <other_name>BAL4815</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive (ethinyl estradiol / norethindrone)</intervention_name>
    <description>contraceptive pill consisting of ethinyl estradiol and norethindrone</description>
    <arm_group_label>Isavuconazole and oral contraceptive</arm_group_label>
    <other_name>Ortho-Novum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18
             to 32 kg/m2, inclusive

          -  Results for aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
             total bilirubim must not be above upper limit of normal range

          -  The subject must be postmenopausal, defined as at least 2 years since the last regular
             menstrual cycle and have follicle stimulating hormone (FSH) &gt; 30 IU/L

        Exclusion Criteria:

          -  The subject has had treatment with hormone replacement therapy within 3 months prior
             to Day -1

          -  The subject has a history of adverse events with taking oral contraceptives or hormone
             replacement therapy

          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac
             arrhythmia or torsade de pointes, structural heart disease, or family history of Long
             QT syndrome (suggested by sudden death of a close relative at a young age due to
             possible or probable cardiac causes)

          -  The subject has a positive result for hepatitis C antibodies or hepatitis B surface
             antigen at Screening or is known to be positive for human immunodeficiency virus (HIV)

          -  The subject has a known or suspected allergy to any of the components of the trial
             products or the azole class of compounds, or a history of multiple and/or severe
             allergies to drugs or foods (as judged by the investigator), or a history of severe
             anaphylactic reactions

          -  The subject is a smoker (any use of tobacco or nicotine containing products) within 6
             months prior to Screening

          -  The subject has had treatment with prescription drugs or complementary and alternative
             medicines within 14 days prior to Day -1, or over-the-counter medications within 1
             week prior to Day -1, with the exception of acetaminophen up to 2 g/day

          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse,
             as defined by the investigator, or a positive drug and/or alcohol screen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>isavuconazole</keyword>
  <keyword>ethinyl estradiol</keyword>
  <keyword>norethindrone</keyword>
  <keyword>contraceptive</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>BAL8557</keyword>
  <keyword>BAL4815</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Mestranol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

